Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine liposome
- Development stage
- Approved
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Daunorubicin and cytarabine liposome is a liposomal-encapsulated formulation that delivers daunorubicin and cytarabine in a fixed 5:1 molar ratio. This formulation is designed to improve the treatment of acute myeloid leukemia (AML) by sustaining exposure to cytotoxic concentrations of both drugs. It has demonstrated improved overall survival compared to the traditional "7+3" regimen in newly diagnosed therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC). The drug was approved by the US Food and Drug Administration (FDA) in 2017 and by the European Medicines Agency (EMA) in 2018 for these specific indications.
- Brand names
- Vyxeos
- Other names
- liposome-encapsulated daunorubicin-cytarabineDaunorubicin, Cytarabine Liposomes
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin and cytarabine liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine liposome.